Senolytics改善老年身体功能并延长健康寿命

发布:2026年7月22日更新:2026年7月22日

Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM等

Nature Medicine · 2018; 24(8):1246-1256

本综述评估Intermittent oral senolytic drugs dasatinib (5 mg/kg) plus quercetin (50 mg/kg), given for short periods (e.g., 3 days every 2 weeks or similar intermittent schedule)与Physical function (grip strength, walking speed, endurance, daily activity) and remaining lifespan的关系。纳入 150 例受试者。证据等级：V。

摘要速览

循证研究：Senolytics改善身体功能并延长健康寿命

医学审核:WellAlly 编辑团队最后审核 2026年7月22日编辑政策

关键信息一览

DOI: 10.1038/s41591-018-0092-9
PMID: 29988130
PMC: PMC6082705
期刊: Nature Medicine
年份: 2018
卷: 24
期: 8
页码: 1246-1256
研究类型: 动物实验
证据等级: V
样本量: 150
干预措施: Intermittent oral senolytic drugs dasatinib (5 mg/kg) plus quercetin (50 mg/kg), given for short periods (e.g., 3 days every 2 weeks or similar intermittent schedule)
主要终点: Physical function (grip strength, walking speed, endurance, daily activity) and remaining lifespan
随访时长: Several months until natural death after treatment started in late life
资金来源: NIH
效应量: 36% increase in remaining lifespan after treatment began; significant improvements in multiple physical function measures
开放获取: 否

研究概述

本研究纳入 150 例受试者，探讨了Intermittent oral senolytic drugs dasatinib (5 mg/kg) plus quercetin (50 mg/kg), given for short periods (e.g., 3 days every 2 weeks or similar intermittent schedule)对Physical function (grip strength, walking speed, endurance, daily activity) and remaining lifespan的影响。

关键发现

研究结果为Physical function (grip strength, walking speed, endurance, daily activity) and remaining lifespan提供了重要证据。

临床结论

详见原始文献。证据等级：V。

Abstract

"本研究共纳入 150 例受试者，探讨了Intermittent oral senolytic drugs dasatinib (5 mg/kg) plus quercetin (50 mg/kg), given for short periods (e.g., 3 days every 2 weeks or similar intermittent schedule)对Physical function (grip strength, walking speed, endurance, daily activity) and remaining lifespan的影响。

Funding & conflicts of interest

资金来源: NIH

COI: Authors hold patents related to senolytics; some have equity or consulting ties to companies developing these drugs